Table 1. Testing and treatment parameters used including estimated ranges around each parameter.

Parameter	Best estimate	Lower range	Upper range	Distribution	Reference
Testing for H.pylori
Breath test
Sensitivity (%)	95.3	92.2	97.5	95%CIa	[16]
Specificity (%)	97.7	94.8	99.3	95%CI	[16]
Serology
Sensitivity (%)	92	85	96	IQRb	[14]
Specificity (%)	83	73	92	IQR	[14]
Stool Antigen
Sensitivity (%)	94	93	95	95%CI	[15]
Specificity (%)	97	96	98	95%CI	[15]
Gastroscopy with biopsy
Sensitivity (%)	95	90	99		[36]
Specificity (%)	99	95	100		[36]
Treatment of H. pylori
HP7 efficacy	77%	27%	97%	full range	[29], [37]
2nd line treatment efficacy	90%	85%	95%		[38]
Sequential therapy efficacy	93%	91%	95%	95%CI	[37]
Benefits of H.pylori eradication
Reduction in gastric cancers	RRc 0.56	RR 0.4	RR 0.8	95%CI	[7]
Reduction in duodenal ulcers	RR 0.37	RR 0.26	RR 0.53	95% CI	[22]
Other
Incidence of Peptic Ulcer disease	0.19%	0.10%	0.19%		[39]
Prevalence of Peptic Ulcer disease	1.50%	0.12%	1.50%		[39]
Incidence of duodenal ulcer if H. pylori +ve	5%	0.18%	17%	95% CI	[21]
Treatment adverse effects (all)
Comparison	8%				[22]
Treatment	22%				[22]
Cancer Survival (%)
1 year	41	39	42	95%CI	[5]
2 year	26	25	28	95%CI	[5]
3 year	21	19	22	95%CI	[5]
4 year	18	16	19	95%CI	[5]
5 year	16	14	17	95%CI	[5]

^aCI  =  95% Confidence Interval.

^bIQR  =  Interquartile range.

^cRR  =  Relative Risk.